Pharmaceutical formulations derived from Aristolochiaceae herbs, which contain aristolochic acids (AAs), are widely used for medicinal purposes. However, exposure to these plants and isolated AAs is linked to renal toxicity, known as AA nephropathy (AAN). Currently, the mechanisms underlying AAN are not fully understood, leading to unsatisfactory treatment strategies. In this study, we explored the protective role of 84-B10 (5-[[2-(4-methoxyphenoxy)-5-(trifluoromethyl) phenyl] amino]-5-oxo-3-phenylpentanoic acid) against AAN. RNA-seq analysis revealed that the mitochondrion and peroxisome were the most affected cellular components following 84-B10 treatment in AAN mice. Consistently, 84-B10 treatment preserved mitochondrial ultrastructure, restored mitochondrial respiration, enhanced the expression of key transporters (carnitine palmitoyltransferase 2) and enzymes (acyl-Coenzyme A dehydrogenase, medium chain) involved in mitochondrial fatty acid β-oxidation, and reduced mitochondrial ROS generation in both aristolochic acid I (AAI)-challenged mice kidneys and cultured proximal tubular epithelial cells. Additionally, 84-B10 treatment increased the expression of key transporters (ATP binding cassette subfamily D) and rate-limiting enzymes (acyl-CoA oxidase 1) involved in peroxisomal fatty acid β-oxidation and restored peroxisomal redox balance. Knocking down LONP1 expression diminished the protective effects of 84-B10 against AAN, suggesting LONP1-dependent protection. In conclusion, our study provides evidence that AAN is associated with significant disturbances in both mitochondrial and peroxisomal functions. The LONP1 activator 84-B10 demonstrates therapeutic potential against AAN, likely by maintaining homeostasis in both mitochondria and peroxisomes.
| [1] |
Das S, Thakur S, Korenjak M, et al. Aristolochic acid-associated cancers: a public health risk in need of global action[J]. Nat Rev Cancer, 2022, 22(10): 576-591.
|
| [2] |
Zhang Q, Luo P, Chen J, et al. Dissection of targeting molecular mechanisms of aristolochic acid-induced nephrotoxicity via a combined deconvolution strategy of chemoproteomics and metabolomics[J]. Int J Biol Sci, 2022, 18(5): 2003-2017.
|
| [3] |
Li P, Pit WN, Lean YL, et al. Herbal products containing aristolochic acids: a call to revisit the context of safety[J]. J Herb Med, 2021, 28: 100447.
|
| [4] |
De Araújo F, Nogueira C, Trichez V, et al. Anti-hyperglycemic potential and chemical constituents of Aristolochia triangularis Cham. leaves-a medicinal species native to Brazilian forests[J]. J Ethnopharma Col, 2023, 303: 115991.
|
| [5] |
Yang B, Xie Y, Guo M, et al. Nephrotoxicity and Chinese herbal medicine[J]. Clin J Am Soc Nephrol, 2018, 13(10): 1605-1611.
|
| [6] |
Gökmen M, Cosyns J, Arlt V, et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review[J]. Ann Intern Med, 2013, 158(6): 469-477.
|
| [7] |
Anandagoda N, Lord G. Preventing aristolochic acid nephropathy[J]. Clin J Am Soc Nephrol, 2015, 10(2): 167-168.
|
| [8] |
Ren J, Rudemiller NP, Wen Y, et al. The transcription factor Twist1 in the distal nephron but not in macrophages propagates aristolochic acid nephropathy[J]. Kidney Int, 2020, 97(1): 119-129.
|
| [9] |
Wang X, Xue N, Zhao S, et al. Upregulation of miR-382 contributes to renal fibrosis secondary to aristolochic acid-induced kidney injury via PTEN signaling pathway[J]. Cell Death Dis, 2020, 11(8): 620.
|
| [10] |
Baudoux TE, Pozdzik AA, Arlt VM, et al. Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy[J]. Kidney Int, 2012, 82(10): 1105-1113.
|
| [11] |
Wang Y, Liu Z, Ma J, et al. Lycopene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system[J]. Redox Biol, 2022, 57: 102494.
|
| [12] |
Jin C, Miao X, Zhong Y, et al. The renoprotective effect of diosgenin on aristolochic acid I-induced renal injury in rats: impact on apoptosis, mitochondrial dynamics and autophagy[J]. Food Funct, 2020, 11(9): 7456-7467.
|
| [13] |
Jo DS, Park NY, Cho DH. Peroxisome quality control and dysregulated lipid metabolism in neurodegenerative diseases[J]. Exp Mol Med, 2020, 52(9): 1486-1495.
|
| [14] |
Di Cara F, Savary S, Kovacs WJ, et al. The peroxisome: an up-and-coming organelle in immunometabolism[J]. Trends in Cell Biology, 2023, 33(1): 70-86.
|
| [15] |
Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited[J]. Annu Rev Biochem, 2006, 75: 295-332.
|
| [16] |
Braverman NE, D'Agostino MD, Maclean GE. Peroxisome biogenesis disorders: biological, clinical and pathophysiological perspectives[J]. Dev Disabil Res Rev, 2013, 17(3): 187-196.
|
| [17] |
Lodhi IJ, Semenkovich CF. Peroxisomes: a nexus for lipid metabolism and cellular signaling[J]. Cell Metab, 2014, 19(3): 380-392.
|
| [18] |
Schrader M, Kamoshita M, Islinger M. Organelle interplay-peroxisome interactions in health and disease[J]. J Inherit Metab Dis, 2020, 43(1): 71-89.
|
| [19] |
Vasko R. Peroxisomes and kidney injury[J]. Antioxid Redox Signal, 2016, 25(4): 217-231.
|
| [20] |
Vasko R, Ratliff BB, Bohr S, et al. Endothelial peroxisomal dysfunction and impaired pexophagy promotes oxidative damage in lipopolysaccharide-induced acute kidney injury[J]. Antioxid Redox Signal, 2013, 19(3): 211-230.
|
| [21] |
Wanders R, Baes M, Ribeiro D, et al. The physiological functions of human peroxisomes[J]. Physiol Rev, 2023, 103(1): 957-1024.
|
| [22] |
Wozny M, Di Luca A, Morado D, et al. In situ architecture of the ER-mitochondria encounter structure[J]. Nature, 2023, 618(7963): 188-192.
|
| [23] |
Shai N, Yifrach E, van Roermund C, et al. Systematic mapping of contact sites reveals tethers and a function for the peroxisome-mitochondria contact[J]. Nat Commun, 2018, 9(1): 1761.
|
| [24] |
Mattiazzi Usaj M, Brloznik M, Kaferle P, et al. Genome-wide localization study of yeast Pex11 identifies peroxisome-mitochondria interactions through the ERMES complex[J]. J Mol Biol, 2015, 427(11): 2072-2087.
|
| [25] |
Li Y, Huang D, Jia L, et al. Lonp1 links mitochondria-ER interaction to regulate heart function[J]. Research (Wash DC), 2023, 6: 715.
|
| [26] |
Bai M, Wu M, Jiang M, et al. LONP1 targets HMGCS2 to protect mitochondrial function and attenuate chronic kidney disease[J]. EMBO Mol Med, 2023, 15(2): e16581.
|
| [27] |
Fan J, Xu X, Li Y, et al. A novel 3-phenylglutaric acid derivative (84-B10) alleviates cisplatin-induced acute kidney injury by inhibiting mitochondrial oxidative stress-mediated ferropto- sis[J]. Free Radic Biol Med, 2023, 194: 84-98.
|
| [28] |
Su M, Liu X, Zhao Y, et al. In silico and in vivo pharmacokinetic evaluation of 84-B10, a novel drug candidate against acute kidney injury and chronic kidney disease[J]. Molecules, 2023, 29(1): 159.
|
| [29] |
Chen J, Luo P, Wang C, et al. Integrated single-cell transcriptomics and proteomics reveal cellular-specific responses and microenvironment remodeling in aristolochic acid nephro- pathy[J]. JCI Insight, 2022, 7(16): e157360.
|
| [30] |
Pozdzik AA, Salmon IJ, Debelle FD, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation[J]. Kidney Int, 2008, 73(5): 595-607.
|
| [31] |
Kayhan M, Vouillamoz J, Rodriguez DG, et al. Intrinsic TGF-β signaling attenuates proximal tubule mitochondrial injury and inflammation in chronic kidney disease[J]. Nat Commun, 2023, 14(1): 3236.
|
| [32] |
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene[J]. ARC Monogr Eval Carcinog Risks Hum, 2002, 82: 1-556.
|
| [33] |
Xian Z, Tian J, Zhang Y, et al. Study on the potential nephrotoxicity and mutagenicity of aristolochic acid IVa and its mechanism[J]. Biomed Pharmacother, 2021, 142: 112081.
|
| [34] |
Deshwal S, Fiedler KU, Langer T. Mitochondrial proteases: multifaceted regulators of mitochondrial plasticity[J]. Annu Rev Biochem, 2020, 89: 501-528.
|
| [35] |
Gabaldon T. Peroxisome diversity and evolution[J]. Philos Trans R Soc Lond B Biol Sci, 2010, 365(1541): 765-773.
|
| [36] |
Xu L, Sharkey D, Cantley LG. Tubular GM-CSF promotes late MCP-1/CCR2-mediated fibrosis and inflammation after ischemia/reperfusion injury[J]. J Am Soc Nephrol, 2019, 30(10): 1825-1840.
|
| [37] |
Lu C, Lei W, Sun M, et al. Identification of CCR2 as a hub in septic myocardial injury and cardioprotection of silibinin[J]. Free Radic Biol Med, 2023, 197: 46-57.
|
| [38] |
Helmke A, Nordlohne J, Balzer MS, et al. CX3CL1-CX3CR1 interaction mediates macrophage-mesothelial cross talk and promotes peritoneal fibrosis[J]. Kidney Int, 2019, 95(6): 1405-1417.
|
| [39] |
Gu X, Weng R, Hou J, et al. Endothelial miR-199a-3p regulating cell adhesion molecules by targeting mTOR signaling during inflammation[J]. Eur J Pharmacol, 2022, 925: 174984.
|
Funding
National Key Research and Development Program of China(2019YFA0802- 702-1)
National Key Research and Development Program of China(2022YFC2705100)
National Key Research and Development Program of China(2022YFC2705105)
National Natural Science Foundation of China(82070701)
National Natural Science Foundation of China(82090022)
National Natural Science Foundation of China(8183- 0020)
Natural Science Foundation of Jiangsu Province(BK 20231130)
Social Development Foundation of Jiangsu Province(BE2021607)
“333” Talent Plan of Jiangsu Province(333-2022001)
Medical Research Project from Jiangsu Health and Health Commission(Z2022071)
Outstanding Youth Project from Nanjing Health and Health Commission(JQX22010)
PDF
(2701KB)
